Dissociation of the ADC in the blood of the tissue can result in damage to normal tissue and can affect the therapeutic effect. Therefore, the design of the drug conjugation is required to take into account the stability of the antibody drug complex and the separation and killing effect after entering the target cell.
The conjugates include both cleavable and non-cleavable. The cleavable conjugates are designed to stabilize in the blood pH environment and hydrolyze in the pH environment of the cells, thereby releasing cytotoxic drugs and killing cancer cells. However, clinical studies have shown that such ADC drugs can undergo non-specific hydrolysis in some cases to cause side effects.
Non-cleavable conjugates are often associated with degradation of ADC drugs, which are often linked to small molecules to lysine and cysteine ​​of degradable monoclonal antibodies during degradation of ADC platform.
https://www.creative-biolabs.com/adc/platform.htm